Compare Adaptive Biotechnologies Corp (ADPT) vs Gold Fields Limited (GFI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Gold Fields Limited — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Gold Fields Limited trades at $32.89 (market cap $30.01B). The key difference: Gold Fields Limited is far larger — about 9× Adaptive Biotechnologies Corp's market cap, and Gold Fields Limited pays a 6.91% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GFI | |
|---|---|---|
Market Cap | $3.33B | $30.01B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $61.52 |
52-Week Low | $10.24 | $23.36 |
Enterprise Value | $3.19B | $31.46B |
Dividend Yield | — | 6.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Gold Fields (GFI) trades at $33.58, down 5.3% over 24 hours, reflecting recent bearish technical momentum. The stock shows strong fundamentals with a P/E of 8.78 and robust profitability margins, including a 40.76% net income margin. Recent earnings have been mixed, with a Q1 2025 beat but subsequent misses. Cash flow improved significantly in 2025, and the balance sheet remains solid despite rising debt levels. Analyst sentiment is divided with a 44% buy rating amid operational challenges and gold price volatility.
The outlook for GFI hinges on execution at key mines like Salares Norte and gold price stability. Upside potential exists from strong cash generation and shareholder returns, but risks include cost inflation and geopolitical pressures. The current valuation appears attractive if operational targets are met, though near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
